Regeneron Pharmaceuticals, Inc. is targeting GPR75 to develop a method to inhibit its expression using ASO or the CRIPSR/Cas system in hopes of treating obesity.291. The gene discussed is GPR75; the disease is obesity due to melanocortin 4 receptor deficiency.